Mirum Pharmaceuticals is entering what could be its most transformative period. The rare disease specialist faces a packed calendar of clinical data readouts that will shape its long-term commercial trajectory, while its financial performance signals a decisive move toward sustained profitability.
Financial Performance Sets the Stage
Operationally, Mirum is demonstrating significant scaling. Company leadership has provided a 2026 product revenue forecast ranging from $630 million to $650 million. This projection represents a meaningful increase over the $521.3 million reported the previous year. A critical milestone for investors was reached in the third quarter of 2025, when the company posted its first-ever net profit, underscoring the scalability of its business model.
Market sentiment, however, has recently reflected a degree of investor caution. Shares closed at €77.00 on Friday, trading approximately 17% below the 52-week high set in February. The stock’s elevated volatility, measured at nearly 55%, highlights the market’s nervous anticipation of the upcoming clinical results.
The next significant update for shareholders is anticipated in late April or early May, when Mirum will disclose its first-quarter 2026 financials. This report will be closely scrutinized to determine if LIVMARLI, the flagship revenue driver which recently contributed over $90 million per quarter, continues to meet high growth expectations.
Should investors sell immediately? Or is it worth buying Mirum Pharmaceuticals?
A Sequential Wave of Clinical Data
The company’s clinical pipeline is poised for several near-term catalysts that will define its expansion potential. The Volixibat program is a primary focus, with topline data from the Phase 2b VISTAS study in primary sclerosing cholangitis (PSC) expected in the second quarter of 2026. A positive outcome here would mark a major step in broadening Mirum’s therapeutic portfolio.
Furthermore, the hepatitis delta virus program for brelovitug is advancing, with 24-week results anticipated in the second half of 2026. These data are intended to form the foundation for a potential U.S. regulatory submission.
The clinical agenda for the year is precisely scheduled:
* Q2 2026: Volixibat data from the VISTAS study in PSC.
* H2 2026: 24-week results for brelovitug in hepatitis delta.
* Q4 2026: Phase 3 data for LIVMARLI from the EXPAND study.
The convergence of these clinical milestones with the company’s accelerating revenue and path to profitability sets the stage for a potentially defining year for Mirum Pharmaceuticals.
Ad
Mirum Pharmaceuticals Stock: Buy or Sell?! New Mirum Pharmaceuticals Analysis from May 13 delivers the answer:
The latest Mirum Pharmaceuticals figures speak for themselves: Urgent action needed for Mirum Pharmaceuticals investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from May 13.
Mirum Pharmaceuticals: Buy or sell? Read more here...
